These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 16720239)

  • 1. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
    Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
    Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective targeting of E. coli heat-stable enterotoxin analogs to human colon cancer cells.
    Giblin MF; Sieckman GL; Watkinson LD; Daibes-Figueroa S; Hoffman TJ; Forte LR; Volkert WA
    Anticancer Res; 2006; 26(5A):3243-51. PubMed ID: 17094436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and in vitro evaluation of an 111In-labeled ST-peptide enterotoxin (ST) analogue for specific targeting of guanylin receptors on human colonic cancers.
    Gali H; Sieckman GL; Hoffman TJ; Kiefer GE; Chin DT; Forte LR; Volkert WA
    Anticancer Res; 2001; 21(4A):2785-92. PubMed ID: 11724355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical synthesis of Escherichia coli ST(h) analogues by regioselective disulfide bond formation: biological evaluation of an (111)In-DOTA-Phe(19)-ST(h) analogue for specific targeting of human colon cancers.
    Gali H; Sieckman GL; Hoffman TJ; Owen NK; Mazuru DG; Forte LR; Volkert WA
    Bioconjug Chem; 2002; 13(2):224-31. PubMed ID: 11906259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone.
    Liu D; Overbey D; Watkinson LD; Daibes-Figueroa S; Hoffman TJ; Forte LR; Volkert WA; Giblin MF
    Anticancer Res; 2009 Oct; 29(10):3777-83. PubMed ID: 19846908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers.
    Giblin MF; Gali H; Sieckman GL; Owen NK; Hoffman TJ; Volkert WA; Forte LR
    Breast Cancer Res Treat; 2006 Jul; 98(1):7-15. PubMed ID: 16724166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer.
    Liu D; Overbey D; Watkinson LD; Smith CJ; Daibes-Figueroa S; Hoffman TJ; Forte LR; Volkert WA; Giblin MF
    Bioconjug Chem; 2010 Jul; 21(7):1171-6. PubMed ID: 20536242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
    Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
    Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula S; Kuji I; Hamacher KA; Konishi S; Kostakoglu L; Kothari PA; Milowski MI; Nanus DM; Bander NH; Goldsmith SJ
    J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model.
    Miao Y; Hoffman TJ; Quinn TP
    Nucl Med Biol; 2005 Jul; 32(5):485-93. PubMed ID: 15982579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a ¹⁷⁷Lu-labeled RGD derivative for targeting angiogenesis.
    Ju CH; Jeong JM; Lee YS; Kim YJ; Lee BC; Lee DS; Chung JK; Lee MC; Jeong SY
    Cancer Biother Radiopharm; 2010 Dec; 25(6):687-91. PubMed ID: 21204763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
    Wolfe HR; Mendizabal M; Lleong E; Cuthbertson A; Desai V; Pullan S; Fujii DK; Morrison M; Pither R; Waldman SA
    J Nucl Med; 2002 Mar; 43(3):392-9. PubMed ID: 11884500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
    Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Zhang H; Chen J; Waldherr C; Hinni K; Waser B; Reubi JC; Maecke HR
    Cancer Res; 2004 Sep; 64(18):6707-15. PubMed ID: 15374988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.